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BIOCHEMICAL JOURNAL
Heterozygous	mutations	in	the	gene	encoding	fibroblast	growth	factor	10	(FGF10)	or	
its	cognate	receptor,	FGF‐receptor	2	IIIb	(FGFR2‐IIIb)	result	in	two	human	
syndromes	‐	LADD	(lacrimo‐auriculo‐dento‐digital)	and	ALSG	(Aplasia	of	lacrimal	
and	salivary	glands).	To	date,	the	partial	loss‐of‐FGF10	function	in	these	patients	has	
been	attributed	solely	to	perturbed	paracrine	signalling	functions	between	FGF10‐
producing	mesenchymal	cells	and	FGF10‐responsive	epithelial	cells.	However,	the	
functioning	of	a	LADD‐causing	G138E	FGF10	mutation,	which	falls	outside	its	
receptor	interaction	interface,	has	remained	enigmatic.	In	this	study,	we	interrogated	
this	mutation	in	the	context	of	FGF10’s	protein	sequence	and	threedimensional	
structure,	and	followed	the	subcellular	fate	of	tagged	proteins	containing	this	or	
other	combinatorial	FGF10	mutations,	in	vitro.	We	report	that	FGF10	harbours	two	
putative	nuclear	localization	sequences,	termed	NLS1	and	NLS2,	which	individually	
or	co‐operatively	promote	nuclear	translocation	of	FGF10.	Furthermore,	FGF10	
localizes	to	a	subset	of	dense	fibrillar	components	of	the	nucleolus.	G138E	falls	
within	NLS1	and	abrogates	FGF10’s	nuclear	translocation	whilst	attenuating	its	
progression	along	the	secretory	pathway.	Our	findings	suggest	that	in	addition	to	its	
paracrine	roles,	FGF10	may	normally	play	intracrine	role/s	within	FGF10‐producing	
cells.	Thus,	G138E	may	disrupt	both	paracrine	and	intracrine	function/s	of	FGF10	
through	attenuated	secretion	and	nuclear	translocation,	respectively. 
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Abbreviations (in alphabetical order):  
ALSG   – aplasia of lacrimal and salivary glands syndrome 
ARPE   – human retinal pigment epithelial cells 
ATDC5  – chondrogenic mesenchymal cells 
βCOP   – coat protein (coatomer) β 
β-Kap   – β-karyopherin, also called importin- β 
DFC   – dense fibrillar components 
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ER   – endoplasmic reticulum 
ERp60  – an isoform of Protein disulphide-isomerase 
FGF   – fibroblast growth factor 
FGFR   – fibroblast growth factor receptor 
GAPDH  – glyceraldehyde 3-phosphate dehydrogenase 
H-bond  – hydrogen bonds 
HA   – Hemagglutinin A 
HMW   – high molecular weight 
LADD   – lacrimo-auriculo-dento-digital syndrome 
LMW   – low molecular weight 
M phase  – mitosis phase of cell cycle 
NLS   – nuclear localisation sequence 
NoBP   – nucleolar binding protein 
PNGase F – Peptide -N-Glycosidase F 
RT-PCR  – reverse transcription polymerase chain reaction 
SDS   – sodium dodecyl sulfate 
SMAD       – amalgam of ‘mothers against decapentaplegic’ (MAD) (Drosophila) and 
‘small body size’ (SMA) (C.elegants) 
TGN46  – trans-Golgi network integral membrane protein 2 
UBF   – upstream binding factor 
WT   – wild type 
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ABSTRACT 
Heterozygous mutations in the gene encoding fibroblast growth factor 10 (FGF10) or 
its cognate receptor, FGF-receptor 2 IIIb (FGFR2-IIIb) result in two human 
syndromes - LADD (lacrimo-auriculo-dento-digital) and ALSG (Aplasia of lacrimal 
and salivary glands). To date, the partial loss-of-FGF10 function in these patients 
has been attributed solely to perturbed paracrine signalling functions between 
FGF10-producing mesenchymal cells and FGF10-responsive epithelial cells. 
However, the functioning of a LADD-causing G138E FGF10 mutation, which falls 
outside its receptor interaction interface, has remained enigmatic. In this study, we 
interrogated this mutation in the context of FGF10’s protein sequence and three-
dimensional structure, and followed the subcellular fate of tagged proteins containing 
this or other combinatorial FGF10 mutations, in vitro. We report that FGF10 harbours 
two putative nuclear localization sequences, termed NLS1 and NLS2, which 
individually or co-operatively promote nuclear translocation of FGF10. Furthermore, 
FGF10 localizes to a subset of dense fibrillar components of the nucleolus. G138E 
falls within NLS1 and abrogates FGF10’s nuclear translocation whilst attenuating its 
progression along the secretory pathway. Our findings suggest that in addition to its 
paracrine roles, FGF10 may normally play intracrine role/s within FGF10-producing 
cells. Thus, G138E may disrupt both paracrine and intracrine function/s of FGF10 
through attenuated secretion and nuclear translocation, respectively.    
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SUMMARY 
G138E, a LADD-syndrome causing FGF10 mutation, falls within a putative NLS motif 
and disrupts FGF10’s nuclear trafficking as well as secretion. G138E may reduce the 
bioavailability of FGF10 for intracrine function/s within FGF10-producing cells and 
paracrine signalling in FGF10-responsive cells. 
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INTRODUCTION  
 LADD (OMIM 149730) and ALSG (OMIM 180920) are rare autosomal dominant 
syndromes caused by a spectrum of heterozygous missense mutations in FGF10 
and FGF-Receptor 2 (FGFR2) genes [1-4](Table 1). These syndromes are 
characterised by defects in tear and saliva production, accompanied by subtle 
craniofacial, limb, pulmonary and urogenital abnormalities, complementary to milder 
phenotypes observed in mice that are heterozygous for FGF10 or its cognate 
receptor, FGFR2-IIIb [5, 6]. Structural modelling and biochemical studies have 
attributed the human defects to impaired FGF10-FGFR2-IIIb interaction, or 
production of unstable proteins [7] (Table 1). Three of the FGF10 mutations occur 
outside its receptor-interacting interface, with two of these (W169X and K137X) 
predicted to generate a truncated non-functional protein (Table 1). However, the 
mechanism by which the third mutation – a Glycine (G) to Glutamic Acid (E) 
substitution at residue 138 - causes LADD [4] is unknown, and its apparent lack of 
involvement in receptor binding has raised the interesting possibility that FGF10 
functions in multiple ways.  
Fibroblast growth factors (FGFs) are a 22-member strong family of 17-34 kDa 
proteins with critical roles in embryonic and adult tissue growth and homoeostasis 
[8]. FGFs have been classified into subfamilies according to peptide sequence 
homology, shared biochemical properties and biological functions. Most FGFs are 
secreted ligands, signalling through one of four tyrosine kinase trans-membrane 
FGFRs, in cooperation with sulphated proteoglycans. FGF-FGFR binding specificity 
is determined in part by alternative splicing of exons encoding FGFRs’ third 
Immunoglobulin-like domains, yielding the so-called ‘IIIb’ and IIIc’ isoforms. 
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Moreover, paracrine signalling and functionality is determined by tissue-specific and 
mutually exclusive expression of FGF ligands and their corresponding receptors. 
Typically, FGF10 is secreted by mesenchymal cells to regulate epithelial cell growth 
and branching morphogenesis by activating the epithelially-expressed FGFR2-IIIb 
isoform [9-11]. 
In addition to their paracrine signalling role, several FGFs are thought to function 
cell-autonomously, via intracellular partnership with scaffolding proteins [12]; 
receptor and non-receptor mediated re-uptake into cells [13]; interaction with FGFRs 
within endosomes [14]; and translocation into the nucleus/ nucleolus [15]. In some 
FGFs, this functional diversity is achieved via the generation and differential 
targeting of low versus high molecular weight (HMW) isoforms. For example, HMW 
FGF2 translocates to the nucleus to stimulate cell proliferation and negatively 
regulate bone mineralization [16, 17]. In contrast, nuclear FGF3 inhibits cell 
proliferation [18].  
Since the LADD-causing G138E mutation lies outside the FGF10-FGFR2 interaction 
interface, in this study we sought alternative explanation/s for its loss-of-function 
effects. Using bioinformatics, structural modelling, site-directed mutagenesis and 
intracellular trafficking analysis, we show that FGF10 harbours two putative nuclear 
localization sequences (NLS), with G138E falling within one of these. In contrast to 
the wild type, rat proteins bearing the equivalent mutation (G145E), or compound 
mutations in a second putative NLS site, fail to traffic into the nucleus and become 
hyper-glycosylated in the cytoplasm. Moreover, G145E fails to progress through the 
intracellular secretory pathway, and transient overexpression of wild type or FGF10 
mutant proteins inhibit mesenchymal cell proliferation and differentiation in vitro. Our 
results suggest that nuclear trafficking promoted by two putative NLS motifs may be 
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an important aspect of FGF10 functionality. Hence, G138E mutation may work by 
reducing the bioavailability of FGF10 at two levels – as a secreted form to FGF10-
responding cells, and as a nuclear form within FGF10-producing cells themselves.  
 
Material and METHODS  
Bioinformatics analysis 
Primary protein sequences were obtained from UniProt database and sequence 
alignments were performed using ClustalW2. Protein 3D models were constructed in 
Chimera 1.9 using RCSB Protein Data Bank files (1nun). The search for NLS 
sequences was performed on rat and mouse FGF10 sequences using NLStradamus 
and NucPred software tools (Suppl. Fig. 1), freely available online. 
Cloning and generation of mutant constructs 
Using the appropriate restriction enzyme or HA tag encoding primers, a C-terminus 
HA-tagged FGF10 construct (FGF10-HA) was generated by PCR from a template 
plasmid encoding rat FGF10 cDNA (gift of Prof. Saverio Bellusci). These were 
scanned for undesirable mutations by Sanger sequencing before cloning as an 
EcoRI-NotI fragment into a mammalian expression vector, pN1, replacing an existing 
mCherry encoding fragment (Suppl. Fig. 2A; Clonetech Laboratories Inc.). All point 
mutation-bearing FGF10 inserts (i.e. R/K to T substitutions) were generated by PCR 
using a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies), 
and the relevant custom designed mutation-bearing primers (Suppl. Fig. 2B). At the 
end of each reaction, residual WT FGF10-HA template was cleaved by DpnI 
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restriction digest, and the desired mutation-bearing products were selected by 
Sanger sequencing. 
Cell cultures and plasmid transfections 
Human retinal pigment epithelial (ARPE19) and embryonic kidney (293T) cells were 
maintained in DMEM/F12 HAMs supplemented with 10% Foetal Bovine Serum 
(FBS; Invitrogen), respectively, supplemented with 0.1% gentamycin or 1% 
penicillin/streptomycin and 1% GlutaMAX (Gibco). ATDC5 cells were grown in 
DMEM/F12 HAMs (Gibco 21331) supplemented with 5% FBS; 1% 
penicillin/streptomycin; 1% GlutaMAX; 30 nM sodium selenite and 10 µg/ml human 
Transferrin. Primary brain cultures were established by enzymatic digest and 
dissociation of freshly isolated hypothalamus from brains of 3-6 weeks old wild type 
mice. Hypothalamic cells were then grown as a monolayer in DMEM/F12 HAMs 
(Gibco 21331) supplemented with 5% FBS; 1% penicillin/streptomycin; 1% 
GlutaMAX; B27 Supplement (Gibco); 35 µg/ml bovine pituitary extract (Invitrogen) 
and 20 ng/ml each of EGF and FGF2 (Peprotech). For transient transfections, cells 
were seeded at 10 to 40x103 on poly-D-lysine (20µg/ml) coated glass coverslips 
placed in a 12- or 24-well plate. At 80% confluency, cells were transfected for four 
hours using JetPrime Reagent (Polyplus transfections) allowing 1 part DNA to 2 
Parts JetPrime, aiming for 1µg of plasmid DNA per well. At 24h, 48h or 72h post 
transfection, cells were fixed for 15 minute in a 4% paraformaldehyde (PFA; pH 7.4) 
solution. 
Immunohistochemistry, Microscopy and Imaging 
In preparation for immunolabelling, PFA-fixed cells were treated with 1% NP-40 and 
blocked in 10% Normal Goat Serum (NGS) solution for 1 hour at room temperature, 
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before overnight incubation at 4⁰C with primary antibodies diluted in 0.2% NGS/PBS. 
These were: Mouse anti-HA (1:1000; Cell Signalling); Rat anti-BrdU (1:1000; Thermo 
Scientific PA5-33256): Rabbit anti-TGN46, ERP60 and βCOP (1:500 each; kind gift 
of Prof T. Wileman and Dr. P. Powell); and Rabbit anti-Fibrillarin (1:1000; Abcam). 
Cells were washed 3-5 times in 0.2% NGS/PBS and the relevant species-specific 
secondary antibodies conjugated to Alexa488 or Alexa568 (1:1000) were applied for 
1h at room temperature. Coverslips carrying immunolabelled cells were mounted 
onto glass slides using Vectashield mounting medium (Vector Labs) and visualised 
using a Zeiss Axioplan2 microscope, with or without an Apotome attachment, under 
identical optical threshold settings. Images were acquired and processed using 
Axiovision 4.8 and ImageJ softwares. A typical experiment (per construct) was 
comprised of transfecting two coverslips and taking measurements from ten random 
areas ie, five from each coverslip. Within each photographed area, total cell number 
(ranging from 60-110 cells per area) as well as the proportion of transfected cells 
was determined, with the latter comprising about 20-30% of the total. The pattern of 
HA localization in each transfected cell was classified into three categories: 
exclusively or predominately nuclear; exclusively or predominantly cytoplasmic; and 
equal cyptoplasmic and nuclear distribution.   
The degree of HA-tag and secretory pathway marker colocalization was measured 
using Volocity 6.3 software. Briefly, 10 randomly selected fluorescent cells from each 
immunolabelling combination were photographed under the relevant channels - red 
(Alexa 568) for HA and green (Alexa 488) for secretory pathway markers (either 
ERp60, βCOP or TGN46). After setting the appropriate thresholds, a scatter plot of 
co-localising markers was generated, from which Pearson’s Correlation coefficient 
(Rr) was calculated. Values range from -1.0 to 1.0, where values above 0.5 signify 
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co-localisation, and values below 0.5 indicate negative or no significant correlation 
between markers. 
Subcellular Fractionation 
Cell fractionation (cytoplasmic versus nuclear) was carried out following the protocol 
of Dimauro et al. [19]. In brief, 24 hours post transfection, 293T cells were washed in 
cold PBS, and pelleted. Cytoplasmic fraction was extracted by treating cells with 
STM buffer (250 mM sucrose; 50 mM Tris–HCl pH 7.4; 5 mM MgCl2) in the presence 
of 1% Halt protease inhibitor cocktail (Thermo Fisher Scientific). Cells were then 
washed in STM buffer, precipitated in pre-cooled acetone and re-suspended in STM 
buffer. The nuclear fraction was extracted in NET buffer (20 mM HEPES pH 7.9; 1.5 
mM MgCl2; 0.5 M NaCl; 0.2 mM EDTA; 20% glycerol; and 1% TritonX-100) in the 
presence of 1% Halt cocktail, incubated on ice for 45 min and centrifuged at 9000 xg 
to remove debris. 
Western Immunoblotting 
ARPE cells cultured on 10cm petri dishes were transfected with 3µg of relevant 
plasmids, and 24 hours later lysed in ice-cold modified RIPA buffer (150mM NaCl; 
50mM Tris; 1.25mM EDTA; 1% Triton, 1% sodium deoxycholate; and 0.1% SDS) 
containing protease inhibitors. Total protein concentration was determined using a 
BCA assay kit (Thermo Fisher Scientific) and cell lysates were stored at -20⁰C until 
use. Protein lysate was subjected to SDS/PAGE, electrophoretic semi-dry transfer to 
nitrocellulose membranes, and incubated with primary mouse antibodies against β-
actin (1:1000) and HA (1:1000; Cell Signalling) at 4⁰C for 24h. Subsequently, HRP-
conjugated goat-anti-mouse antibodies were applied (1:1000) and membranes were 
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incubated in ECL solution (100mM Tris pH8; 1.25mM luminol; 0.2 mM coumaric acid; 
and 0.01% H2O2) and exposed to Hyperfilm ECL (for 5-30 seconds for β-actin; 15 
minutes for HA). 
Cell Proliferation assays 
20 hour post-transfection with the relevant constructs, ATDC5 cells were pulsed with 
3µg/ml BrdU for 4 hours, fixed in 4% PFA, and treated with 1M HCl at 47ºC for 
30min before sequential immunolabelling with mouse anti-HA and rat anti-BrdU 
antibodies and the relevant fluorophore-tagged secondary antibodies. One hundred 
cells expressing HA were examined for expression of BrdU. The experiment was 
repeated three times on different occasions, using cells of similar passage number. 
ATDC5 cell differentiation assays 
ATDC5 cells were grown to 90% confluency in 24-well plates. To induce 
differentiation, growth medium was supplemented with 50 µg/ml ascorbic acid 
(Sigma) and Insulin-Transferrin-Selenium solution ITS–G (Gibco, 1:100 dilution). 
Cells were transfected three times, first on the day of differentiation and every two 
days thereafter, with HA-tagged constructs or a control pmCherry-N1 vector. Some 
cells were additionally treated with 10ng/ml FGF10 (Peprotech). Differentiated 
mesenchymal condensations/ nodules normally appeared within 14 days. After 16 
days in culture, cells were fixed for 10 min with 4% paraformaldehyde at RT, and 
treated for 5 min at -20oC with pre-chilled absolute methanol. Differentiated cells 
were revealed by 30 min staining with 0.5% Alcian blue in 0.1M HCl at RT. After 
photographing the stained cells, Alcian blue was extracted by a 6-hour incubation at 
RT with 6M guanidine hydrochloride, and quantified using a spectrophotometer at 
630nm. Each treatment was replicated 4 times.  
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Detection of Fgf10 and FGF-Receptor isoforms by standard Rt-PCR 
mRNA was isolated from HEK293T cells as well as differentiated undifferentiated 
ATDC5 cells using Trizol reagent, and subjected to Rt-PCR to detect Fgf10, the IIIb 
and IIIc isoforms of FGF-receptors 1-3 and FGFR4-IIIc, using previously described 
primers, protocols and cycle conditions [20, 21].	   
Statistical analysis 
Raw data was imported into and analysed by IBM SPSS Statistic 22 software.  
Normally distributed data of equal variance were compared using Student’s t Test 
(for two samples), or ANOVA post hoc Tukey (for greater than two samples). 
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RESULTS  
Putative Nuclear Localisation Sequences within FGF10  
To investigate the mode/s of G145E function, we considered a potential intracellular 
mechanism involving nuclear trafficking. Active nuclear import of proteins requires 
nuclear localization sequence (NLS) motif/s, typically composed of a short stretch of 
positively charged amino acids such as arginine and lysine. NLS motifs can occur 
anywhere within a protein sequence, but must be exposed at the surface to allow for 
interaction with adaptor proteins such as importin-α and β-Kap, which facilitate 
protein trafficking through the nuclear pore complex [22]. 
Using two independent software algorithms, NLStradamus [23] and NucPred [24] we 
identified a putative NLS motif encoded by amino acids 194 to 202 (RRGQKTRRK). 
This is in addition to a more N-terminal NLS-like sequence (rat residues 
142NKKGKLY148) noted by Kosman et al. [25] resembling, but not homologous to, a 
putative NLS found in FGF1 (i.e YKKPKLL). Here on we term these NLS2 and NLS1, 
respectively (Fig. 1; Suppl. Fig. 1A,B). Sequence alignments revealed that both 
NLS1 and NLS2 are fully conserved between rat, mouse and human, and show high 
conservation amongst other vertebrates (Fig. 1A). Moreover, 3D-modelling showed 
that both motifs are exposed and reside away from the FGF10-FGFR2 interaction 
interface (Fig. 1B). Strikingly, the LADD-type G138E falls within NLS1, and the G138 
residue (rat G145) is not only conserved among different mammalian species (Fig. 
1A) but also across different FGF family members (Suppl. Fig. 1C,D). To understand 
the significance of this high conservation, we scrutinized structural models of FGF10 
and found that G145 interacts via a single H-bond with residue 196 (G196) of NLS2. 
Furthermore, side chains of the basic residues within NLS2 extend away from the 
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protein surface (Fig. 1C) allowing for potential contacts and interactions with other 
molecules, such as importins. Combined, these analyses suggested that NLS1 and 
NLS2 may function individually or co-operatively to promote nuclear import of 
endogenous FGF10. 
Glycine 145 is critical for nuclear translocation of FGF10 
To test the idea that FGF10 can translocate into the nucleus, we first analysed its 
cellular distribution. In the absence of commercial antibodies to specifically detect 
endogenously produced FGF10 by immunocytochemistry (our unpublished 
investigations), we followed the fate of FGF10 molecules tagged at their C-terminus 
with Haemagglutinin A (FGF10-HA). The relevant construct was generated by PCR 
from rat cDNA and cloned into pN1 mammalian expression vector (Addgene; Suppl. 
Fig. 2A). ARPE (retinal pigment epithelial) cells were transiently transfected with the 
corresponding vector and FGF10-HA was detected by anti-HA immunolabelling, at 
24, 48 and 72 hours post transfection. Although a variety of cellular HA distributions 
were observed, consistently in 20-25% of transfected cells, HA was predominantly 
nuclear, regardless of time-point analysed (Fig. 2A,B). This was not peculiar to 
ARPE cells, as similar extent of nuclear HA localization were found in transfected 
ATDC5 (chondrogenic mesenchymal) cells; primary adult mouse hypothalamic cells 
and HEK293T cells (Fig. 2A,B; data not shown). Moreover, a similar pattern and 
proportion of nuclear FGF10-HA was observed after transfection of serum-starved 
growth arrested cells, suggesting that its nuclear localization is not dependent on 
nuclear membrane breakdown during M phase (Fig. 2C; data not shown). On closer 
examination, some cells exhibited discrete nucleolar FGF10-HA localization (see 
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also below). Generation of Fgf10 transcripts from transfected plasmids was 
confirmed by real time Rt-PCR (data not shown). 
Because LADD-causing G138E falls within a putative NLS (NLS1), next we asked 
whether introducing the mutant protein into cultured cells affects its nuclear 
localization. Thus, a corresponding C-terminus HA-tagged rat G145E construct was 
generated through site-directed mutagenesis (Suppl. Fig. 2), transfected into ARPE 
cells, and analysed as described for wild type FGF10-HA. Generation of G145E-
encoding transcripts was also confirmed by real time Rt-PCR (data not shown). 
Remarkably, in all cell types and at all time points examined, G145E-HA was 
excluded from the nucleus and restricted to the cytoplasm (Fig. 2A,B).  
A glutamic acid substitution at residue 145 would create an acidic side chain, 
potentially disrupting the interaction of FGF10 with importins. On the other hand, a 
glycine residue per se could be critical for the nuclear translocation. To distinguish 
between these possibilities we also analysed the cellular distribution of HA-tagged 
G145V and G145A FGF10 constructs, choosing valine (V) or alanine (A) residue 
substitutions to mimic the small size of the glycine residue. However, both G145V-
HA and G145A-HA molecules behaved like G145E-HA and showed nuclear 
exclusion (Suppl. Fig. 3A-D’; data not shown).  
These findings show that nuclear translocation of FGF10 can occur in multiple cell 
types – at least following its cytoplasmic introduction in our experimental settings. 
Furthermore, a G138E LADD-type amino acid substitution can disrupt this trafficking 
and a glycine residue at position 138 (rat 145) is critical for this process.  
Distinct NLS2 residues are also important for FGF10 nuclear trafficking 
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To determine the functionality and key elements of the NLS2 that may be important 
for nuclear translocation of FGF10, six basic residues (lysine and arginine) at 
positions 194, 195, 198, 200, 201 and 202 were individually mutated to a neutral 
threonine (T) using site directed mutagenesis (Fig. 3A; Suppl. Fig. 2B). In 
anticipation that mutagenesis of single NLS2 residues may not suffice – as observed 
in other NLS-bearing FGFs [26, 27], we also generated three double-mutants 
(R194T/R195T, R200T/R201T and R200T/K202T) and a single quadruple-mutant 
construct (R194T/R195T/R200T/K202T, here on termed 4T-NLS2), all tagged with 
HA at their C-termini (Fig. 3A). These were transfected into ARPE cells and 
subcellular distribution of HA was monitored by immunolabelling alongside sister 
cultures transfected with FGF10-HA or G145E-HA mutant. 
We found that in contrast to G145E (NLS1), single residue substitutions in NLS2 had 
no significant impact on nuclear translocation of FGF10. However, double mutations 
significantly altered the balance of subcellular localization in favour of the cytoplasm, 
and the quadruple mutation (4T-NLS2) mimicked the effect of G145E, excluding 
FGF10 from the cell nucleus altogether (Fig. 3B-D). This was verified by 
immunolabelling of transfected cells, or by immunoprobing their nuclear and 
cytoplasmic protein sub-fractions with antibodies against fibrillarin, a ribonucleolar 
protein, and GAPDH, a cytoplasmically-restricted protein, in combination with HA 
(Fig. 4). First, FGF10-HA clearly co-localised with a subset of dense fibrillar 
components (DFC) found in the nucleolus (Fig. 4A). Second, when compared to wild 
type FGF10, G145E and 4T-NLS appeared more abundant in the cytoplasmic 
fraction (Fig. 4B). Interestingly, wild type FGF10 accumulates largely as its mature 
21kDa form within the nucleus, whilst the cytoplasmic fraction additionally contains 
its 25kDa immature species (see below).   
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Since mutation of NLS2 mimics the effects of G145E mutation in NLS1, these 
findings suggest a distinct cluster of NL2 residues are also important for FGF10’s 
nuclear trafficking, possibly acting independently or through a conformational 
association with NLS1. 
Nuclear-excluded FGF10 mutants undergo hyperglycosylation and disrupt 
FGF10’s secretory pathway 
To assess the molecular consequence of mutations that induce nuclear exclusion, 
whole cell lysates from ARPE cells transfected with wild type or mutant HA-tagged 
constructs were isolated, resolved by SDS page and probed with anti-HA antibodies. 
The efficacy of anti-HA antibodies in these assays was verified using a control vector 
encoding HA-tagged SMAD2, detectable as a 55 kDa product (Fig. 5A). 
Wild type FGF10 is normally detected as a full-length 25kDa product as well as a 
mature 21kDa protein lacking the signal peptide, required for progression through 
the secretory pathway [28, 29]. Here, the 21kDa band was detected in all samples 
except for G145E and G145V (Fig. 5A). In contrast, a novel strong 30kDa species 
was present in the G145E and G145V samples as well as R200T/K202T and 4T-
NLS2, but not in R194/R195T, R194T, K198T single mutants or wild type. We also 
noted that the 25kDa product was generally stronger whenever the 30kDa protein 
was present (Fig. 5A). Based on its size and the reduced conditions of SDS page, 
we posit that the 30kDa product is an unlikely product of intracellular ligand-ligand 
dimerization (>50 kDa) or ligand-FGFR partnership (>110 kDa). Since secreted 
FGFs can be glycosylated at multiple positions and FGF10 is predicted to carry at 
least 26 potential sites (Fig. 5B), we investigated the possibility that the 30kDa 
species represents a hyperglycosylated form of FGF10. Cell lysates containing 
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FGF10-HA, G145E-HA and a selection of single and double mutants as well as the 
4T-NLS2 were subjected to ‘N’ deglycosylation with PNGase F, or to deglycosylation 
with a cocktail of ‘O and N’ degycosylating enzymes. As shown in Fig. 5C, N-
degylcosylation alone was sufficient to reduce not only the 30kDa, but also the 
25KDa products in all samples, to a single 21kDa product. This suggests that ‘O’ 
glycosylation of FGF10 is cultured cells is minimal. 
A likely interpretation of these findings is that whilst abolishing nuclear translocation, 
the LADD-type G145E traps the mutant protein in the cytoplasm, permitting its 
hyperglycosylation with a possible deleterious effect on its secretion. Unfortunately, 
low transfection levels did not permit isolation of sufficient secreted protein from the 
culture media in order to compare the secretory potential of wild type versus mutant 
FGF10, although poor FGF10 secretion from transfected cells has been noted by 
others [29].	   Therefore, as an alternative approach we compared the cytoplasmic 
progression of wild type and G145E along the secretory pathway. 
G145E mutant protein accumulates within the Endoplasmic Reticulum  
To examine progression through the secretory pathway, we compared the 
distribution of FGF10-HA, G145E-HA and 4T-NLS2-HA in three subcellular 
compartments that define the successive stages of secretion. Thus, transfected cells 
were co-immunolabelled with anti-HA as well as antibodies against ERp60, an early 
secretory pathway chaperone within ER; βCOP, a marker of transport between ER 
and Golgi; and TGN46, demarcating Golgi and vehicle transport stages (Schematic, 
Fig. 6A). Close scrutiny of high resolution images from randomly selected cells 
showed that whilst FGF10-HA colocalised with all three markers (Fig. 6B,C,F,I), 
expression of G145E-HA was restricted to the ERp60-positive compartment (Fig. 
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6B,D,G,J), and 4T-NLS2 showed a much weaker phenotype (Fig. 6B,E,H,K). In 
agreement with whole cell lysate analysis (Fig. 5A), these results suggest that the 
G145E mutant protein fails to progress through the secretory pathway. However, the 
causal relationship between nuclear exclusion, hyperglycosylation and secretion 
cannot be wholly ascertained from our experimental approach.  
Proliferation and differentiation of ATDC5 cells is differentially affected by mis-
expression or exogenous treatment with FGF10  
An important function of FGF10 is to regulate the formation and patterning of 
cartilage in vivo [30, 31]. To test whether the perturbation of cellular trafficking 
reported above impacts cell behaviour in vitro, we measured the rate of cell 
proliferation and differentiation in ATDC5 cells – a chondrogenic mesenchymal cell 
line which expresses transcripts for FGF10 and FGFR2-IIIc, and to a lesser degree, 
FGFR1-IIIc, FGFR2-IIIb and FGFR3-IIIc, but not FGFR1-IIIb (Rt-PCR data; not 
shown). Sister cultures of ATDC5 cells transfected with constructs encoding HA-
tagged wild type FGF10, G145E- or 4T-NLS2-bearing mutations, or a control 
mCherry vector, were BrdU-pulsed for 4 hours and then immediately analysed for 
co-expression of BrdU with mCherry or HA.  Compared to mCherry-transfected cells, 
all FGF10-bearing constructs showed a significant reduction in cell proliferation, but 
no significant differences were noted between wild type and mutant constructs (Fig. 
7A-C). Similarly, the level of chemically-induced differentiation of ATDC5 cells into 
Alcian-blue–positive chondrocytes was significantly lower in cells transfected with 
FGF10-carrying constructs, when compared to non-transfected or mCherry 
transfected cultures, with no marked difference between different FGF10-carrying 
constructs (Fig. 7D-J). Separately, we also measured the rate of differentiation of 
20	  
	  
non-transfected ATDC5 cells in response to exogenously applied FGF10 (R&D 
systems; concentration ranges 1, 10 or 100 ng/ml). No discernable effect on cell 
differentiation was noted at 1 or 100 ng/ml, but a higher level of cell death was 
evident at 100ng/ml. However, and in contrast to FGF10 transfections, 10ng/ml of 
exogenous FGF10 promoted ATDC5 cell differentiation, and, supplementation of 
FGF10-HA transfected cultures with exogenous FGF10 partially rescued the 
inhibitory effects of FGF10-HA (Fig. 7I,I’ and J; data not shown). 
In sum, although abrogation of nuclear trafficking does not yield a unique effect, 
over-expression of FGF10, whether wild type or mutant, does perturb the 
proliferation and differentiation of mesenchymal cells in the paradigms tested. This 
suggests that in ATDC5 cells FGF10 may have multiple cell-intrinsic modes of action 
- nuclear and/or non-nuclear.  Nonetheless, the contrasting effects brought about by 
FGF10 transfection vs exogenous FGF10 treatment, indicates that the cell-
autonomous function/s of transfected constructs are unlikely to involve cell surface 
exposed FGFRs. 
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DISCUSSION 
ALSG and LADD syndromes are commonly caused by heterozygous mutations in 
FGF10 or its cognate receptor FGFR2-IIIb, affecting tissues that develop and 
function through epithelial-mesenchymal cross talk, utilising this signalling pathway. 
Most FGF10 mutations are postulated to yield proteins that are truncated, unstable, 
or defective in receptor interactions, explaining their partial loss-of-function effects 
(Table 1). However, the functioning of a FGF10 G138E residue substitution has 
remained enigmatic. In this study, we analysed this mutation in silico and modelled 
the equivalent rat protein (G145E) in vitro. Although we cannot exclude the 
possibility that G138E encodes an unstable protein targeted for rapid degradation in 
vivo, our results rather suggest that falling within a putative NLS sequence, G145E 
works by attenuating the process of FGF10 secretion, coupled to a novel nuclear 
trafficking role. The latter is supported by the identification of a second putative NLS 
sequence within FGF10, the mutation of which also abrogates FGF10 nuclear 
localization. We propose therefore that the G138E pathology may involve two 
cellular compartments and multiple biological processes ie. attenuation of paracrine 
signalling in epithelial cells secondary to reduced FGF10 secretion by mesenchymal 
cells, as well as perturbed cell-autonomous FGF10 function/s in mesenchymal cells 
themselves (summarised schematically in Suppl. Figure 7). 
Nuclear translocation of FGF10 and its putative functions 
As a 21-25 kDa protein, FGF10 is in principle small enough to passively traffic in and 
out of the nuclear pore complex and attain an equal nuclear/ cytoplasmic cell 
distribution at any given time. However, we found that most transiently transfected 
cells exhibit predominantly cytoplasmic or nuclear FGF10 as late as 72 hours post 
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transfection, suggesting that FGF10 is actively compartmentalized and/or retained 
within the cell nucleus. This phenomenon is not a peculiarity of our transfection 
system since Kosman et al [25] showed that exogenously applied FGF10 can enter 
the cell nucleus, possibly in association with FGFRs. They also reported that 
mutagenesis of basic residues flanking G145 in NLS1 can diminish, but not 
abrogate, this route of nuclear localization. By contrast, we showed that the mutation 
of the evolutionary conserved glycine 145 alone abrogates both FGF10’s nuclear 
localization and progression along the secretory pathway. It may be that the basic 
residues of NLS1 have a dual function of binding FGFRs and promoting nuclear 
entry. Interestingly, an arginine 187 to valine substitution in mouse NLS2 (Rat 
R194V) alters FGF10’s extracellular receptor binding dynamics and converts it to an 
FGF7-like molecule in branching morphogenesis assays [32]. In our assays, 
mutation of R194 alone (to threonine) did not affect the normal rate of FGF10 
nuclear trafficking, perturbing this function only in combination with other mutations 
in NLS2. 
Dynamics and mechanisms of nuclear translocation notwithstanding, the significance 
and role of nuclear-targeted FGF10 molecules remains unknown. We showed that 
FGF10 becomes localized to a subset of dense fibrillar components of the nucleolus, 
demarcated by the expression of Fibrillarin. The nucleolus is important for the 
generation and assembly ribosomal RNA as well as non-coding RNAs involved in 
pre-mRNA splicing and protein synthesis, and, formation of RNA-telomerase 
complexes [33]. Hence, it is tempting to speculate that by associating with the 
molecular machinery of the nucleolus, FGF10 participates in one or more of the 
above processes to regulate gene expression or cell cycle control, akin to roles 
ascribed to nucleolar FGF2 and FGF3.  Nucleolar FGF2 directly regulates synthesis 
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of ribosomal RNA and stimulates Polymerase I transcription through binding to UBF 
transcription factor [34]. Nucleolar FGF3 is postulated to inhibition cell proliferation 
by binding to NoBP protein [35].  
Targeting of FGF10 to the nucleus could also play a critical stoichiometric role in 
regulating the normal level of paracrine FGF10 signalling. Numerous studies show 
that the level of FGFR signalling is exquisitely regulated and is critical for multiple 
biological outcomes during normal development as well as pathological conditions 
[10]. A key factor in this process is the quantity and bioavailability of FGF ligands. 
For example, FGF10 is a driver of hyperactive FGFR2 mutations that cause Apert 
syndrome, and its genetic knockdown in a mouse model of Apert syndrome rescues 
much of the related defects [36]. Hence, the amount of secreted FGF10, available for 
paracrine signalling in epithelial cells, may normally be determined by titration 
against its nuclear-targeted forms in mesenchymal cells.   
A potential cell autonomous role for FGF10 within FGF10-expressing cells 
themselves, whether nuclear or otherwise, gains credence from the discovery of 
tissues wherein FGF10 is unconventionally expressed in the epithelial cell 
compartment, or, from which FGF10’s cognate receptor, FGFR2-IIIb is absent. 
Notably, FGF10 is atypically expressed in the developing Otic epithelium [37]	  where it 
regulates cell specification, in contrast to its paracrine regulation of cell proliferation 
or differentiation. Interestingly, a significant number of LADD syndrome patients 
suffer from hearing defects [1]. In the adult brain (hypothalamus), expression of 
FGF10 by a population of neural stem cells termed tanycytes, is not complimented 
by FGFR2-IIIb or FGFR1-IIIb expression, where the IIIc isoforms of FGFRs 1-3 
predominate. Tanycytes produce new appetite/energy balance regulating neurons in 
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vivo [38] and we showed that FGF10 can translocate into the nucleus of these cells 
in vitro (Fig. 1A). Thus, it would be interesting to investigate whether partial-loss-of 
FGF10 function in LADD/ALSG patients perturbs the homeostatic functions of 
hypothalamus, such as energy expenditure.   
In summary, our in vitro investigations of a LADD-syndrome FGF10 point mutation 
has led us to postulate novel mechanisms involving defects in secretion linked to 
nuclear translocation of FGF10. This may not be a common mode of function in all 
LADD/ALSG mutations, as evidenced by the diversity and varying degrees of 
phenotypic penetrance in these patients. Nonetheless our results highlight another 
potential level of complexity in FGF10 biology during normal development and in 
disease, warranting further investigations using inducible constructs to fine dissect 
the intermediate steps of FGF10 trafficking, or in vivo modelling of distinct LADD 
mutations in transgenic animal models to test the differential role of individual 
mutations.   
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Table and figure legends 
Table 1. Spectrum of LADD/ALSG syndrome causative mutations 
Current spectrum of mutations in FGF10 or FGFR2-IIIb that results in ALSG and 
LADD syndromes, with their predicted or characterised molecular properties. Star (*) 
denotes FGF10 mutations occurring outside its cognate receptor’s binding site. To 
date, the mode of action for a G138E mutation (rodent equivalent, G145E) has 
remained unknown. A rare FGFR3 mutation has also been described [2]. 
 
Figure 1. Structure, conservation and positioning of two putative NLS motifs in 
FGF10 
A) Amino acids encoding putative NLS1 (green) and NLS2 (Red) in FGF10 show a 
high degree of conservation from fish to mammals. B) Three dimensional modelling 
viewed from two angles to show close proximity of NLS1 (green) and NLS2 (red) 
motifs and their surface exposure away from FGF10’s (light brown) interaction 
interface with FGFR2-IIIb (blue). C) Capacity for a direct hydrogen bond (blue line) 
between carboxyl oxygen of G145 residue in NLS1 (purplue) and amide hydrogen of 
G196 in NLS2, and, lateral protrusion of NLS2 basic residues (R194, R195, K198, 
R200, R201 and K202) away from FGF10 molecule. 
 
Figure 2. LADD-type G145E mutation inhibits the normal nuclear trafficking of 
FGF10 
26	  
	  
A) Transiently transfected HA-tagged FGF10 is found in both the cytoplasm and 
nucleus of multiple cell types, whereas an HA-tagged G145E mutant is absent from 
cell nucleus. Images, 24 hours post transfection. B) Temporal quantification of 
nuclear/ cytoplasmic localisation shows a time-independent difference between 
FGF10-HA and G145E in ARPE cells (Error bars – SE; ANOVA **** p≤0.0001; n=3). 
C) Nuclear translocation of FGF10-HA can occur in growth arrested ARPE cells. 
Scale bars: 50 µm in A, 25 µm in C.  
 
Figure 3. Combinatorial mutation of distinct residues in NLS2 mimic the 
nuclear exclusion effect of G145E in NLS1 
A) Single and combinatorial theronine (T) residue substitutions in NLS2, created by 
site-directed mutagenesis. B) Quantitative comparison of nuclear/ cytoplasmic 
localization of NLS2 mutants with wild type FGF10-HA and G145E mutant in ARPE 
cells (Error bars - SE; ANOVA **** p≤0.0001; n=4). C, D) Representative images of 
ARPE cells transfected with HA-tagged single or multiple NLS2 mutant constructs, 
demonstrating nuclear exclusion in a subset of these mutants, particularly 4T-NLS2 
(quantified in B). Scale bars: 50 µm in C and D. 
 
Figure 4. Association of FGF10-HA with cell nucleolus and molecular 
compartmentation of wild type and mutant FGF10 proteins 
A) Co-localisation of HA and a nucleolus-restricted protein, Fibrillarin, demonstrates 
clear association of FGF10-HA with a subset of nucleolar aggregates (arrows). B) 
Use of anti-Fibrillarin and GAPDH to compare molecular abundance of FGF10-HA, 
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G145E and 4T-NLS2 in cytoplasmic and nuclear fractions of transfected cells. A 
control m-Cherry construct, probed by anti-Ds-Red antibodies, is found in both 
fractions and no HA is found in non-transfected cells. Note, mutant proteins are 
relatively more abundant in the cytoplasmic fractions. Scale bar in A: 25 µm. 
 
Figure 5. NLS mutations perturb the molecular processing of FGF10 
A) Characteristics of HA-tagged WT and mutant FGF10 proteins, immunoprobed 
with anti-HA antibodies. A 25kDa full-length immature FGF10 protein is observed in 
all lanes, but the nuclear-excluded mutant forms (lanes 2, 3, 7 and 8) additionally 
show a 30kDa product. 21kDa signal-peptide lacking mature form of FGF10 fails to 
be produced by NLS1 mutants (lanes 2 and 3). Lane 9, positive control for HA; Lane 
10, non-transfected control. B) Location of at least 26 potential glycosylation sites on 
rat FGF10 protein sequence: ‘O’-linked in italics; ‘N’-linked in bold. C) Treatment of 
WT and mutant proteins with de-glycosylating reagents abrogates the 30 and 25kDa 
products in favour of a 21kDa product.  
 
Figure 6. Abnormal cytoplasmic retention and trans-Golgi trafficking of G145E 
and 4T-NLS molecules 
A) A schematic of the trans-Golgi secretion pathway and protein markers 
delineating its intermediate steps: ERp60 (early ER stage); βCOP and TGN46 (late 
ER stages). B) Quantification of immuno-colocalisation between these markers and 
HA-tagged FGF10, G145E and 4T-NLS2 molecules (shown in panels C-K), using 
Pearson’s Correlation coefficient (see methods). FGF10-HA and 4T-NLS2 show 
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values above 0.5, indicative of colocalisation with all three markers, whereas G145E 
co-localises only with the ERp60. C-K) ARPE cells transfected with FGF10-HA 
(C,F,I), G145E (D,G,J) and 4T-NLS2 (E,H,K), and probed with Trans-Golgi secretion 
pathway markers, showing that whilst the WT protein is processed through the 
pathway, the G145E is sequestered at the ER stage. Scale bars: 20 µm in all panels. 
 
Figure 7. Effects of FGF10 over-expression or exogenous treatment on ATDC5 
cell proliferation and differentiation  
A-B’) Examples of ATDC5 cells transiently transfected with FGF10-HA or a control 
mCherry construct, and pulsed with BrdU. C) Introduction of FGF10-HA or its mutant 
forms significantly reduces cell proliferation when compared to a control mCherry 
vector. (D-I’) Representative low and high power images of ATDC5 cells induced to 
differentiate in 24-well plates without any transfection (D,D’), or after transfection with 
a mCherry control (E,E’); FGF10-HA and its mutant forms alone (F-H’); or FGF10-
HA, in the presence of exogenous FGF10 (I,I’). Transfection with FGF10-HA or its 
mutant forms delays the differentiation of ATDC5 cells, evidenced by formation of 
fewer Alcian blue-positive nodules and lower spectrophotometric detection of Alcian 
blue (J). (I,I’,J) Exogenously-applied FGF10 partially rescues the inhibitory effects of 
FGF10-HA transfection. Scale bars: 20 µm in A; 1000 µm in D,E,F,G,H and I; 100 
µm in D’,E’,F’,G’,H’ and I’. (Error bars in C, J are SE; ANOVA *p≤0.05; **p≤0.01, 
***p≤0.001, ****p≤0.0001. C, n=5; J, n=4). 
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Supplementary Figures 
Suppl. Figure 1. Bioinformatic analysis of putative NLS sequences in FGF10. 
A, B) Use of NLStradamus and NucPred highlights a weak NLS (here termed NLS2) 
site in rat Fgf10 exon 3, encoded by amino acids 194 to 202 and conserved across 
species (Figure 1A). C, D) Full conservation of Glycine 145 residue in rat NLS1 
within related FGF7 subfamily members (C), as well as different FGFs (D).  
 
Suppl. Figure 2. P-N1 cloning vector backbone and site-directed mutagenesis 
primers sequences. 
A) Schematic diagram of pN1 mammalian expression vector carrying mCherry, used 
as control. HA-tagged WT or mutant FGF10 constructs were cloned into this vector 
as EcoRI-NotI tagged PCR fragments, replacing mCherry. B) Primer sequences 
used for HA and restriction enzyme tagging; PCR amplification of FGF10 from a rat 
cDNA plasmid (gift of Prof. Saverio Bellusci); and site-directed mutagenesis. Single 
base pair substitutions inducing site-directed mutagenesis are shown in bold (second 
row and rows below it). 
 
Suppl. Figure 3. Importance of Glycine residue 145 (rat) to FGF10’s nuclear 
trafficking. 
A, C) Structural modelling showing the substitution of glycine 145 in NLS1 with two 
larger amino acids, valine (A, A’) or alanine (C, C’), coloured purple. B,D), Nuclear 
exclusion of both HA-tagged G145V (B, B’) and HA-tagged G145A (D, D’) FGF10 
30	  
	  
molecules in cultured cells (B,D), mimicking the G145E mutation. Scale bars: 20 µm 
in panels B,D. 
 
Suppl. Figure 4.  Putative modes of FGF10 function during normal 
development, and partial-loss-of function in LADD. 
A) FGF10 is produced mainly by mesenchymal cells and regulates epithelial cell 
biology through paracrine action. However, it may have important cell-intrinsic 
function/s within the cytoplasm of mesenchymal cells themselves or through 
translocation into their nucleus. B) The likes of G145E (Human G138E) mutations 
that occur outside FGF10-FGFR2IIIb interaction interface, may induce LADD by 
affecting both epithelial and mesenchymal cell biology. i.e. by reducing the level of 
FGF10 available for paracrine signalling, and abrogating FGF10’s nuclear 
translocation within mesenchymal cells. As an engineered compound mutation, 4T-
NLS would not occur naturally but nonetheless its effects partially mimic that of 
G145E to show the importance of putative NLS sequences within FGF10. 
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Table 1. Spectrum of LADD/ALSG syndrome causative mutations 
Mutation/ 
Deletion
Amino acid 
change Syndrome Molecular consequence Reference/s
Entesarian et al. 2007 
Chapman et al. 2009
Rohmann et al. 2006;
Shams et al. 2007
Deletion (of exons 
2 and 3) Not applicable ALSG No protein product Entesarian et al. 2005
409A→T (exon 2) K137X* ALSG & LADD Predicted truncated protein Milunsky et al. 2006
413G→A (exon 2) G138E* ALSG/LADD Unknown Entesarian et al. 2007
430G→A (intron 2) n/a ALSG Truncated protein Scheckenbach et al. 2008
Milunsky et al. 2006; 
Shams et al. 2007
506G→A (exon 3) W169X* ALSG Predicted truncated protein Milunsky et al. 2006
577C→T (exon 3) R193X ALSG
Truncated protein; partial 
abrogation of FGF10/ 
FGFR2-IIIb binding
Entesarian et al. 2005
620A→C (exon 3) H207P No discernable phenotype Rare polymorphism Entesarian et al. 2007
Mutation/ 
Deletion
Amino acid 
change Syndrome Molecular consequence Reference/s
1882G→A A628T LADD
Although within ligand-
binding domain, affects 
tyrosine kinase catalytic 
activity
Rohmann et al. 2006; 
Shams et al 2007;       
Lew et al. 2007                                  
1942G→A        
(exon 16) A648T LADD Affects ligand binding Rohmann et al. 2006
∆1947-AGA-1949 
base depletion 
(exon 16)
R649S & 
∆D650 LADD Affects ligand binding Rohmann et al. 2006
FGF10 mutations
317G→T (exon 1) C106F* LADD Product unstable at physiological temperature
237G#→A (exon 1) W79X ALSG Predicted truncated protein Seymen et al. 2016
FGFR2 mutations
240A→C (exon 1) R80S ALSG Disruption of FGF10/ FGFR2-IIIb binding site
467T→G (exon 2) I156R LADD Disruption of FGF10/ FGFR2-IIIb binding site
